NewAmsterdam Pharma Company N.V. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.94 | -$0.21 | -$0.57 |
| Q2 2024 | 1 | -$0.88 | -$0.19 | -$0.54 |
| Q3 2024 | 2 | -$0.73 | -$0.16 | -$0.45 |
| Q4 2024 | 6 | -$0.50 | -$0.44 | -$0.47 |
| Q1 2025 | 3 | -$0.47 | -$0.42 | -$0.45 |
| Q2 2025 | 2 | -$0.73 | -$0.16 | -$0.44 |
| Q3 2025 | 2 | -$0.70 | -$0.15 | -$0.43 |
| Q4 2025 | 2 | -$0.69 | -$0.15 | -$0.42 |
| Q1 2026 | 1 | -$0.63 | -$0.14 | -$0.38 |
| Q2 2026 | 1 | -$0.64 | -$0.14 | -$0.39 |
| Q3 2026 | 1 | -$0.68 | -$0.15 | -$0.41 |
| Q4 2026 | 1 | -$0.72 | -$0.16 | -$0.44 |
NewAmsterdam Pharma Company N.V. Earnings Date And Information
NewAmsterdam Pharma Company N.V. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.18 earnings per share for the quarter, topping analysts' consensus estimates of $-0.48 by $0.3. The company had revenue of 29.11 M for the quarter and had revenue of 12.76 M for the year. NewAmsterdam Pharma Company N.V. has generated $-2 earnings per share over the last year ($-2.15 diluted earnings per share) and currently has a price-to-earnings ratio of -10.02. NewAmsterdam Pharma Company N.V. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
NewAmsterdam Pharma Company N.V. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.48 | -$0.18 | 0.3 | $1.87 M | $29.11 M |
| 08/07/2024 | Q2 2024 | -$0.59 | -$0.38 | 0.21 | $1.21 M | $2.13 M |
| 05/08/2024 | Q1 2024 | -$0.54 | -$0.98 | -0.44 | $1.30 M | |
| 02/28/2024 | Q4 2023 | -$0.55 | -$0.52 | 0.03 | $1.59 M | |
| 09/29/2023 | Q3 2023 | -$0.56 | $1.88 M | |||
| 08/07/2023 | Q2 2023 | -$0.39 | -$0.43 | -0.04 | $1.57 M | |
| 08/07/2023 | Q1 2023 | -$0.39 | -$0.47 | -0.08 | $7.96 M | |
| 03/31/2023 | Q4 2022 | -$0.61 | -$2.06 | -1.45 | $1.29 M | |
| 11/28/2022 | Q3 2022 | -$23.19 | $5.62 M | |||
| 06/28/2022 | Q2 2022 | $0.75 | $46.75 M | |||
| 03/29/2022 | Q1 2022 | $0.75 | $46.75 M | |||
| 12/30/2021 | Q4 2021 | -$1.73 | $0 | |||
| 09/29/2021 | Q3 2021 | -$0.82 | $0 | |||
| 06/29/2021 | Q2 2021 | -$0.43 | $0 | |||
| 03/30/2021 | Q1 2021 | -$0.43 | $0 | |||
| 12/30/2020 | Q4 2020 | $0.00 | $0 | |||
| 09/29/2020 | Q3 2020 | -$0.02 | $0 | |||
| 06/29/2020 | Q2 2020 | -$0.02 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.02 | $0 |
NewAmsterdam Pharma Company N.V. Earnings: Frequently Asked Questions
-
When is NewAmsterdam Pharma Company N.V.'s earnings date?
NewAmsterdam Pharma Company N.V. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
-
Did NewAmsterdam Pharma Company N.V. beat their earnings estimates last quarter?
In the previous quarter, NewAmsterdam Pharma Company N.V. (:NAMS) reported $-0.18 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.48 by $0.3.
-
How can I listen to NewAmsterdam Pharma Company N.V.'s earnings conference call?
The conference call for NewAmsterdam Pharma Company N.V.'s latest earnings report can be listened to online.
-
How can I read NewAmsterdam Pharma Company N.V.'s conference call transcript?
The conference call transcript for NewAmsterdam Pharma Company N.V.'s latest earnings report can be read online.
-
How much revenue does NewAmsterdam Pharma Company N.V. generate each year?
NewAmsterdam Pharma Company N.V. (:NAMS) has a recorded annual revenue of $12.76 M.
-
How much profit does NewAmsterdam Pharma Company N.V. generate each year?
NewAmsterdam Pharma Company N.V. (:NAMS) has a recorded net income of $12.76 M. NewAmsterdam Pharma Company N.V. has generated $-2.15 earnings per share over the last four quarters.
-
What is NewAmsterdam Pharma Company N.V.'s price-to-earnings ratio?
NewAmsterdam Pharma Company N.V. (:NAMS) has a price-to-earnings ratio of -10.02 and price/earnings-to-growth ratio is -0.53.
